Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6334
-0.0115-1.78%
Pre-market: 0.64870.0153+2.42%05:38 EDT
Volume:6.43M
Turnover:4.14M
Market Cap:153.92M
PE:-0.85
High:0.6640
Open:0.6310
Low:0.6276
Close:0.6449
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.60
T/O Rate:3.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-14.81
PE(LYR):-0.35

Loading ...

Outlook Therapeutics - Terminates May 13, 2026 Prospectus Supplement for Atm Offering Agreement with H.c. Wainwright - SEC Filing

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics Launches Public Offering with Accompanying Stock Purchase Warrants

Reuters
·
Aug 13

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics - Proceeds to Support Lytenava U.S. Launch, Working Capital, and Corporate Purposes

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Outlook Therapeutics Updates Financial Calendar for Quarterly Results Call and Webcast

Reuters
·
Aug 06

OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

TIPRANKS
·
Aug 01

Outlook Therapeutics Director Faisal Ghiath Sukhtian Acquires 95,398 Common Shares for $99,962.34

Reuters
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS)

TIPRANKS
·
Jul 28

Outlook Therapeutics upgraded to Buy from Neutral at BTIG

TIPRANKS
·
Jul 27

Outlook Therapeutics Inc : Btig Raises to Buy from Neutral

THOMSON REUTERS
·
Jul 27

Outlook Therapeutics Gains Following FDA Approval of Macular-degeneration Drug

Dow Jones
·
Jul 25

NASDAQ Trade Halt Volatility Trading Pause at 03:00 Pm

Reuters
·
Jul 25

Outlook jumps 24% to $1.64 after FDA approves wet AMD treatment

TIPRANKS
·
Jul 25

Outlook Therapeutics Announces Lytenava FDA Approval for Treatment of Wet AMD

Reuters
·
Jul 25

US FDA Approves Outlook Therapeutics' Eye Disease Drug

Reuters
·
Jul 25

Outlook Therapeutics Inc: Anticipated 12 Years of Market Exclusivity Under Biologics Price Competition and Innovation Act

THOMSON REUTERS
·
Jul 25

Outlook Therapeutics - Lytenava Expected to be Available to U.S. Patients Before Year-end

THOMSON REUTERS
·
Jul 25

Outlook Therapeutics Announces Lytenava™ FDA Approval as the First and Only Fda-approved Ophthalmic Bevacizumab for the Treatment of Wet Amd

THOMSON REUTERS
·
Jul 25

Outlook Therapeutics Inc trading halted, news pending

TIPRANKS
·
Jul 25